Plaid Technologies Inc. appointed Guy Bourgeois as its interim Chief Financial Officer effective September 30, 2026, following the resignation of former CFO Gary Dodge. Bourgeois, who is also a director and Corporate Secretary, will oversee the company's financial reporting and regulatory filings. The company plans to search for a permanent CFO and will update once a new appointment is made. This leadership change is important for maintaining financial oversight during the transition period.
Plaid Technologies Inc.'s appointment of an interim CFO is noted here with market data as context. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 02, 2026 03:27 WIB: out of 38 priced US stocks, 7 rose and 30 fell. Albemarle Corp. (ALB) traded at USD 104.55 with a 1-day change of -1.16% and a typical hold time on Pluang of 50 days, while LyondellBasell Industries NV (LYB) was at USD 57.52, down 1.13%. Air Products & Chemicals, Inc. (APD) stood at USD 273.38, down 1.10%, with Pluang order activity showing 58% sell and 42% buy.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
